中際旭創(300308.SZ):凱風進取已減持71.03萬股
格隆匯 7 月 10日丨中際旭創(300308.SZ)公佈,2020年7月10日,公司收到特定股東凱風進取、凱風萬盛出具的《關於股份減持計劃實施進展的告知函》。根據上述告知函的內容,特定股東凱風進取、凱風萬盛股份減持計劃的減持時間已過半,僅凱風進取減持71.03萬股,佔公司總股本比例0.0996%。
截至公告日,凱風進取、凱風萬盛及其一致行動人霍爾果斯凱風旭創創業投資有限公司、霍爾果斯凱風厚澤創業投資有限公司、蘇州永鑫融盛投資合夥企業(有限合夥)合計持有公司5930.3227萬股股份,佔公司總股本的8.3155%,仍為公司合計持股5%以上的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.